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Background: This study aimed to explore parameters which will predict good control of HbA1c after adding a
second anti-diabetic drug in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin
monotherapy.
Methods: Fifty-one patients (M/F: 25/26, mean age: 53.7 ± 8.2 years, mean glycated hemoglobin [HbA1c] 8.4 ± 1.2%)
with T2DM inadequately controlled with metformin were randomized to add-on glibenclamide or acarbose for
16 weeks. Before and after combination therapy, the subjects underwent a 2-hour liquid mixed meal tolerance test
to determine insulin secretion (HOMA-β, insulinogenic index, and disposition index [DI]) and insulin sensitivity
(HOMA-IR and Matsuda insulin sensitivity index).
Results: At baseline, there was a significant inverse relationship between DI120 and HbA1c (p = 0.001) in all subjects.
The addition of glibenclamide and acarbose improved HbA1c significantly from 8.6 ± 1.6% to 7.4 ± 1.2% (p < 0.001),
and from 8.2 ± 0.8% to 7.5 ± 0.8% (p < 0.001), respectively. In the glibenclamide group, DI120 significantly increased
from 51.2 ± 24.2 to 74.9 ± 41.9 (p < 0.05), and in the acarbose group, from 62.5 ± 31.4 to 91.7 ± 36.2 (p < 0.05),
respectively. Multiple regression analyses showed that both baseline HbA1c and DI120 independently predicted
reduction of HbA1c as well as final HbA1c after combination therapy.
Conclusions: In patients with T2DM inadequately controlled with metformin, add-on oral anti-diabetic agent with
glibenclamide or acarbose resulted in the significant HbA1c reduction and improvement of β-cell function. Subjects
with greater baseline β-cell function reserve displayed better glycemic response in the combination therapy of
metformin with glibenclamide or acarbose.
Trial registration: This study was registered in the ClinicalTrials.gov with registration number of NCT00417729.
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Impaired insulin secretion and insulin sensitivity are
the main pathogenic defects in type 2 diabetes mellitus
(T2DM), and can lead to either fasting or postprandial
hyperglycemia [1]. The United Kingdom Prospective Dia-
betes Study (UKPDS) reports that at the diagnosis of
T2DM, the pancreatic β-cell function is already half re-
duced, and then declines continuously despite the allo-
cated therapy [2]. However, insulin insensitivity generally
remains stable for years following the diagnosis [3]. Data
from our group demonstrated that the contribution of
PPG to glycemic control is equal to or greater than that of
FPG across different ranges of HbA1c [4], and that this is
partly accounted by the impaired early secretory defect of
β-cell function in Asians, resulting in a greater contribu-
tion of PPG to overall glycemic control [5,6].
In patients with T2DM, metformin therapy is generally
recommended as the first line medication for glycemic
control [7]. If the patients are unable to achieve or maintain
their glycemic goal, other anti-diabetic agents are usually
required, but which class of drug is more suitable remains
a matter of debate. It has been reported that addition of
sulfonylurea or acarbose can improve glycemic control in
diabetic patients who fail to reach their HbA1c target with
metformin alone, but limited data are available guiding the
add-on class of oral anti-diabetic drug (OAD) in patients
with T2DM inadequately controlled with metformin [7]. At
present, few data are available to study the factors that
influence the glycemic response after addition of gliben-
clamide and acarbose in patients with type 2 diabetes inad-
equately controlled by metformin monotherapy. Because
β-cell dysfunction plays an important role in the progres-
sion of glycemic control in T2DM, it was hypothesized that
underlying β-cell dysfunction may affect the glycemic
control efficacy of the secondary added-on medication.
Therefore, this study aimed to compare the clinical effi-
cacy of addition of glibenclamide and acarbose and evalu-
ate whether β-cell function could predict glycemic control




This was a 24-week, randomized, open-label, parallel study
conducted at Taichung Veterans General Hospital and
Changhua Christian Hospital, Taiwan. Some of the results
of this study were published before [8]. In brief, outpa-
tients with T2DM, who were 30 to 70 year-old and treated
by mono- or dual- OAD therapy for above 3 months with
a HbA1c value of 7.0 to 11.0%, were eligible. Total 51 sub-
jects (mean age, 54 years; females, 51%; mean body mass
index (BMI), 25.6 kg/m2; mean HbA1c, 8.4% were ran-
domized when they were inadequately controlled by met-
formin monotherapy (500 mg 3 times daily) for 8 weeks.Anthropometric data, FPG, HbA1c, and lipid profiles were
measured at baseline (randomization visit) and at the end
of the study after a 16-week treatment with dual oral
hypoglycemic agents. Patients were excluded if they were
treated with insulin or drugs that promote weight loss, had
impaired renal (serum creatinine concentration >1.5 mg/
dL) or liver (aspartate aminotransferase or alanine ami-
notransferase 2.5 times greater than the normal range)
function, had a history of hemoglobinopathy or chronic
anemia, or were women of child-bearing potential without
adequate contraception. During the 16-week period of
dual therapy, dosages were 50 mg TID for acarbose and
2.5 mg TID for glibenclamide for the first 4 weeks. For the
following 12 weeks, dosages were doubled in each group,
if the subjects could tolerate [8]. The present report fur-
ther analyzed the relationship between HbA1c and insulin
secretion/sensitivity indices, and examined whether beta-
cell function and insulin sensitivity were correlated with
glycemic control after add-on glibenclamide or acarbose.
Prior to randomization, a liquid mixed meal tolerance test
(LMTT) was conducted after a 10-hour overnight fast.
The liquid mixed meal contained 355.5 ml and 399 kcal
(caloric contribution: 64% carbohydrate, 14% fat, and 22%
protein). Blood samples were collected for measurement
of serum glucose and insulin concentration at pre-meal
(0 min) and at the 10th min, 20th min, 30th min, 60th min,
90th min, 120th min, and 180th min via an indwelling ven-
ous catheter. AUCglu was determined as the sum of the
basal area and incremental area from 0 min to 120 min.
Insulin sensitivity was estimated by homeostasis model as-
sessment of insulin resistance (HOMA-IR) [9] and the
Matsuda insulin sensitivity index (MISI) [10]. Insulin se-
cretion was estimated by homeostasis model assessment of
β-cell function (HOMA-β) [9] and the insulinogenic
index calculated as the ratio of incremental insulin to
glucose during the first 30 min of the LMTT (Δinsu-
lin to Δglucose = I30 - I0/G30 – G0) [11]. In addition,
because the response of insulin secretion from β-cells
to hyperglycemia is modulated by the severity of insu-
lin resistance, we also used the disposition index (DI),
which is calculated as the product of insulin sensitivity and
insulin secretion [12-14]: early-phase disposition index,
DI30 = [AUCins 30/AUCglu 30] ×MISI and total disposition
index, DI120 = [AUCins 120/AUCglu 120] × MISI. After a
16-week therapy of dual oral hypoglycemic agents, a second
LMTT was performed with all patients. The study was
approved by the Institutional Review Board of Taichung
Veterans General Hospital and Changhua Christian Hospital,
Taiwan, and all subjects provided informed consent.
Laboratory measurements
Plasma glucose was measured by the glucose oxidase–
peroxidase method (Advia 1800; Siemens Healthcare
Diagnostics Inc., Deerfield, Illinois). The inter- and
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insulin was determined using electrochemiluminescence im-
munoassay (Elecsys 2010; Roche Diagnostics, Indianapolis,
Indiana). The inter- and intra-assay%CV for insulin
were 1.8% and 2.5%, respectively. HbA1c was measured by
cation-exchange HPLC (HLC-723 G7; Tosoh Bioscience
Ltd., Worcestershire, United Kingdom). The inter- and
intra-assay%CV for HbA1c were both <4.0%.
Statistical analyses
Data are presented as the mean ± standard deviation for
continuous variables and percentage for categorical vari-
ables. The Chi-square test and Mann–Whitney U test
were used for between-group comparison. Linear regres-
sion analyses were used to determine the relationship be-
tween any one index of insulin sensitivity or secretion and
glucose control parameters, such as baseline HbA1c, FPG,
or (AUCglu) in 120 min after adjustment of age, gender,
baseline BMI, and disease duration. The Wilcoxon signed
rank test was used to analyze the differences in BMI, FPG,
HbA1c, HOMA-IR, HOMA-β, insulinogenic index, MISI,
and DI120 from baseline to the end of the study. In addition,
simple correlation and multiple regression analysis
were conducted to evaluate the independent relationship
between either HbA1c level or the magnitude of HbA1cAssessed for elig
28 completed the study (n=28)
Discontinued intervention (1 withdrew consent) 
(n=1)
Add-on acarbose (50mg TID for 4 weeks, 
uptitrated to 100mg TID for 12 weeks) (n=29; 1 
patient could not tolerate dose titration to 
100mg TID due to abdominal distension)
Randomize
Monotherapy o
500mg TID for 8
Figure 1 CONSORT flow diagram.reduction after combination therapy and background
factors as well as baseline insulin secretion/sensitivity
indices. A p-value of less than 0.05 was considered
statistically significant. Statistical analyses were per-
formed using SPSS version 15.0 (SPSS Inc., Chicago,
Illinois).
Results
The CONSORT flow diagram of this study was shown in
the Figure 1. All of the 51 subjects enrolled in the present
study were treated with metformin (500 mg 3 times daily)
for the first 8 weeks as a washout period. After this period,
28 subjects were treated with metformin and acarbose
while another 23 were treated with metformin and gli-
benclamide for 16 weeks. There was no significant differ-
ence in the clinical characteristics of each group before
randomization (Table 1). Multiple linear regression analyses
were performed to test the association between glucose
control parameters and insulin secretion/sensitivity indices
after metformin monotherapy and before randomization. It
was shown DI120 was the only parameter inversely associ-
ated with HbA1c after adjustment of age, gender, disease
duration, and baseline BMI. Both DI120 and HOMA-β sig-
nificantly correlated with other glucose control parameters,
FPG or AUCglu. As for indices of insulin sensitivity oribility (n=550)
Excluded  (n=495)
Not meeting inclusion criteria (n=450)
Declined to participate (n=45)
Discontinued intervention (2 withdrew consent 
and 1 discontinued due to hypoglycemia) (n=3)
Add-on glibenclamide (2.5mg TID for 4 weeks, 
uptitrated to 5mg TID for 12 weeks) (n=26; 6
patients could not tolerate dose titration to 5mg 
TID due to concern or symptoms of 
hypoglycemia)




Table 1 Baseline characteristics of participants by treatment at randomization
All (n = 51) Glibenclamide (n = 23) Acarbose (n = 28) P value
Gender (female, %) 51.0% 56.5% 46.4% 0.477
Age (years) 53.7 ± 8.2 54.7 ± 8.3 52.8 ± 8.2 0.378
Disease duration (years) 6.9 ± 4.6 6.0 ± 4.7 7.6 ± 4.5 0.106
BMI (kg/m2) 25.6 ± 3.3 25.3 ± 3.8 25.9 ± 3.0 0.334
HbA1c (%) 8.4 ± 1.2 8.6 ± 1.6 8.2 ± 0.8 0.691
Fasting plasma glucose (mmol/l) 8.5 ± 2.3 9.0 ± 3.0 8.2 ± 1.3 0.538
DI30 41.1 ± 25.0 36.8 ± 19.1 44.7 ± 29.0 0.247
DI120 57.3 ± 28.6 51.2 ± 24.2 62.5 ± 31.4 0.289
HOMA-IR 3.7 ± 2.9 4.7 ± 3.9 2.9 ± 1.5 0.316
MISI 3.4 ± 1.8 3.2 ± 1.7 3.6 ± 1.8 0.321
HOMA-β (%) 44.9 ± 40.4 52.3 ± 49.7 38.9 ± 30.4 0.248
Insulinogenic index30 (pmol/mmol) 42.1 ± 63.4 35.0 ± 37.2 47.9 ± 79.0 0.416
Chi-square test. Mann–Whitney U test. Data are presented as mean ± standard deviation or percentage of participants.
DI, disposition index; HOMA-β, homeostasis model assessment β-cell function index; HOMA-IR, homeostasis model assessment insulin resistance index; MISI,
Matsuda insulin sensitivity index.
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FPG (Table 2).
After 16 weeks of dual-OAD therapy, there was a signifi-
cant decrease in FPG and HbA1c values in both groups
(Table 3), and eighteen of the 51 subjects (35.3%) achieved
good glycemic control of HbA1c < 7.0% (9 subjects, 32.1%
in acarbose group and 9 subjects, 39.1% in glibenclamide
group, respectively, p = 0.603). Although there was no dif-
ference in HbA1c between the 2 groups after add-on ther-
apy, the mean HbA1c reduction in the glibenclamide arm
(1.2%) was greater than in acarbose arm (0.7%), that was
compatible with the general concept that sulfonylurea has
a more potent effect upon the magnitude of HbA1c reduc-
tion than acarbose [7]. In addition, the insulin secretion
marker, DI120, improved in both groups, but there was no
significant difference in these insulin secretion/sensitivity
surrogates, and their change before and after combination
therapy between the 2 treatment groups. Multiple linear
regression analyses were performed to test the relationship
between baseline DI120 and HbA1c in all subjects after
combination therapy of metformin with glibenclamide orTable 2 Multiple linear regression analysis between insulin se
parameters before randomization
HbA1c
β 95% CI P
DI120 −0.784 (−0.053,-0.014) 0.001* −
HOMA-β (%) 0.005 (−0.010,0.011) 0.979 −
Insulinogenic index30 (pmol/mmol) 0.341 (−0.001,0.014) 0.075
HOMA-IR −0.068 (−0.223,0.165) 0.764
MISI 0.270 (−0.111,0.488) 0.210
Adjusted for age, gender, body mass index, and disease duration. *P < 0.05.
AUCglu, area under curve of glucose in 120 min; DI, disposition index; HOMA-β, hom
HOMA-IR, homeostasis model assessment insulin resistance index; MISI, Matsuda inacarbose (Table 4). By using the 3 analysis models to ad-
just OAD classes and other possible bias factors, including
age, gender, disease duration, baseline BMI, and other
insulin secretion/sensitivity indices, both baseline HbA1c
and DI120 were significantly associated with HbA1c after
add-on therapy. Likewise, a significant association was also
found between baseline DI120 and the magnitude of HbA1c
reduction after add-on therapy (Table 5). In each sub-
group, simple correlation analysis showed that there was a
negative correlation between baseline DI120 and HbA1c
after dual therapy in acarbose group (r = −0.439, p =
0.022), and in glibenclamide group (r = −0.584, p = 0.003),
respectively.Discussion
The main finding from the present study was that in
those patients with T2DM inadequately controlled by
metformin, residual β-cell function, expressed by DI120,
independently predicted glycemic response after adding
a 2nd OAD, either glibenclamide or acarbose.nsitivity and secretion indices and glucose control
Fasting plasma glucose AUCglu
β 95% CI P β 95% CI P
0.426 (−1.053,-0.148) 0.011* −0.525 (−14.088,-2.496) 0.006*
0.507 (−0.752,-0.262) <0.001* −0.348 (−7.040,-0.759) 0.016*
0.211 (−0.038,0.303) 0.124 0.016 (−2.074,2.296) 0.919
0.484 (2.168,11.302) 0.005* 0.128 (−38.411,78.513) 0.492
0.037 (−6.204,7.882) 0.811 −0.021 (−95.634,84.672) 0.903
eostasis model assessment β-cell function index;
sulin sensitivity index.
Table 3 Comparison of glucose control parameters, insulin secretion and sensitivity surrogates before and after
treatment in both groups
Acarbose (n = 28) Glibenclamide (n = 23)
Before After P-values vs. baseline Before After P-values vs. baseline
BMI (kg/m2) 25.9 ± 3.0 25.5 ± 3.3 0.005* 25.3 ± 3.8 25.5 ± 4.0 0.072
Fasting plasma glucose (mmol/l) 8.2 ± 1.2 7.3 ± 1.2 0.002* 9.0 ± 3.0 7.2 ± 2.1 0.001*
HbA1c (%) 8.2 ± 0.8 7.5 ± 0.8 <0.001* 8.6 ± 1.6 7.4 ± 1.2 <0.001*
HOMA-IR 3.0 ± 1.4 3.1 ± 2.9 0.682 4.8 ± 3.9 3.5 ± 2.7 0.101
HOMA-β (%) 40.3 ± 30.0 49.4 ± 40.2 0.021* 53.7 ± 50.5 47.0 ± 83.4 0.153
Insulinogenic index30 (pmol/mmol) 47.9 ± 79.0 50.6 ± 42.0 0.080 35.0 ± 37.2 36.1 ± 24.5 0.191
MISI 3.6 ± 1.8 4.6 ± 2.8 0.124 3.2 ± 1.7 4.1 ± 2.9 0.176
AUCins 120/AUCglu 120
§(pmol/mmol) 2.9 ± 2.3 3.8 ± 3.1 0.003* 2.7 ± 1.4 3.3 ± 1.7 0.121
DI120 62.5 ± 31.4 91.7 ± 36.2 0.002* 51.2 ± 24.2 74.9 ± 41.9 0.003*
Wilcoxon signed rank test; Data are presented as mean ± standard deviation.
*P <0.05: § total area under curve of insulin within 120 minutes divided by total area under curve of glucose within 120 minutes.
DI, disposition index; HOMA-β, homeostasis model assessment β-cell function index; HOMA-IR, homeostasis model assesment insulin resistance index; MISI,
Matsuda insulin sensitivity index.
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http://www.dmsjournal.com/content/6/1/68It is well recognized that pancreatic β-cell dysfunction is
a key pathogenetic factor involved in T2DM [1]. In 1981,
Bergman et al. [15] postulated the product of insulin sen-
sitivity and insulin secretion was a constant, namely, the
disposition index (DI). This index represents the respon-
siveness of β-cells in compensating for insulin sensitivity
[16]. In general, DI120 represents the overall insulin re-
sponse to insulin sensitivity during oral glucose tolerance
test [12]. In addition, DI120 derived from LMTT also has a
predictive power analogous to that calculated from intra-
venous glucose tolerance test [13,14]. In clinical studies, DI
has been shown to decrease with progression from normalTable 4 Multiple linear regression models of HbA1c after com
Model 1
β P
Drug group (0 = glibenclamide; 1 = acarbose) 0.089 0.4
Gender (0 = female; 1 =male) −0.163 0.1
Age (years) −0.106 0.3
Disease duration (years) 0.105 0.3
BMI (kg/m2) 0.172 0.1
HbA1c (%) 0.677 <0.0
MISI 0.162 0.3
HOMA-IR −0.305 0.0
HOMA-β (%) −0.030 0.8





Multiple linear regression models with HbA1c after combination therapy as the dep
of the second-line OADs.
*P < 0.005; § total area under curve of insulin within 120 minutes divided by total a
DI, disposition index; HOMA-β, homeostasis model assessment β-cell function; HOM
Incremental AUC, incremental area under curve during liquid mixed meal toleranceglucose tolerance to diabetes mellitus, and can be used to
predict the development of diabetes over a long period in a
population without diabetes [17]. Of note, our study also
demonstrated that before randomization, there was a sig-
nificant negative association between DI120 and HbA1c, but
not HOMA-β, insulinogenic index, HOMA-IR, or MISI.
These observations were supported by our previous report
that PPG was an important contributor to glycemic control
[4] and indicated that β-cell dysfunction relative to insulin
sensitivity was a major determinant of HbA1c in Asians.
There was a significant decrease in FPG and HbA1c
values after 16 weeks of dual-OAD therapy in both groups.bination therapy
Model 2 Model 3
β P β P
10 0.152 0.127 0.145 0.126
10 - - - -
07 - - - -
13 - - - -
79 - - - -
01* 0.687 <0.001* 0.703 <0.001*
91 0.217 0.234 - -
80 −0.210 0.148 −0.244 0.085
64 0.029 0.835 - -
34 - - - -
58 0.302 0.150 0.158 0.249
5* −0.743 0.031* −0.552 0.030*
26 0.329 0.176 0.284 0.142
endent variable. All independent variables were collected before randomization
rea under curve of glucose within 120 minutes.
A-IR, homeostasis model assessment insulin resistance index;
test; MISI, Matsuda insulin sensitivity index.
Table 5 Multiple linear regression models of magnitude of HbA1c reduction after combination therapy
Model 1 Model 2 Model 3
β P β P β P
Drug group (0 = glibenclamide; 1 = acarbose) −0.113 0.410 −0.192 0.127 −0.183 0.126
Gender (0 = female; 1 =male) 0.206 0.110 - - - -
Age (years) 0.134 0.307 - - - -
Disease duration (years) −0.132 0.313 - - - -
BMI (kg/m2) −0.217 0.179 - - - -
HbA1c (%) 0.730 <0.001* 0.718 <0.001* 0.698 <0.001*
MISI −0.204 0.391 −0.273 0.234 - -
HOMA-IR 0.384 0.080 0.265 0.148 0.308 0.085
HOMA-β (%) 0.037 0.864 −0.036 0.835 - -
Insulinogenic index30 (pmol/mmol) 0.091 0.734 - - - -
AUCins 120/AUCglu 120
§(pmol/mmol) −0.379 0.258 −0.380 0.150 −0.199 0.249
DI120 1.009 0.045* 0.936 0.031* 0.696 0.030*
DI30 −0.574 0.226 −0.414 0.176 −0.358 0.142
Multiple linear regression models with HbA1c reduction after combination therapy as the dependent variable. All independent variables were collected before
randomization of the second-line OADs.
*P < 0.005; § total area under curve of insulin within 120 minutes divided by total area under curve of glucose within 120 minutes.
DI, disposition index; HOMA-β, homeostasis model assessment β-cell function; HOMA-IR, homeostasis model assessment insulin resistance index;
Incremental AUC, incremental area under curve during liquid mixed meal tolerance test; MISI, Matsuda insulin sensitivity index.
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ated with the magnitude of HbA1c reduction after add-on
therapy. Several factors, including higher baseline HbA1c,
longer disease duration, younger age, and higher BMI have
been reported to be associated with poorer glycemic
control in patients with T2DM [18-20]. However, in the
present study, only baseline HbA1c, but not age, disease
duration, BMI, or gender, independently predicted good
glycemic control after adding glibenclamide or acarbose to
metformin therapy. It was speculated that a small sample
size, short follow-up duration, and limited OAD classes
might be causes of inconsistent results.
In addition to decreased HbA1c after add-on second
OAD, the insulin secretion marker, DI120, also improved
in both groups. It is proposed that ameliorating hypergly-
cemia in subjects with type 2 diabetes might also have a
helpful effect on β-cell failure by attenuating so-called glu-
cose toxicity effect [21]. Particularly, our study also found
that baseline DI120 was an independent predictor of gly-
cemic control after adding glibenclamide or acarbose in
the subjects inadequately controlled by metformin mono-
therapy. It has been reported that β-cell dysfunction can
relate to HbA1c in newly diagnosed T2DM [22,23], or in
already OAD-treated adults with T2DM [24-26]. However,
some of these studies were limited in that they disclosed
only the cross-sectional relationship between β-cell func-
tion and glycemic parameters. Our study findings would
extend the role of β-cell function in predicting the thera-
peutic response of HbA1c levels. This result may be par-
ticularly important in Asian people with diabetes becauseit is proposed that β-cell dysfunction plays a major role in
the pathogenesis of T2DM in this group of patients [5],
and thus can determine HbA1c response after use of oral
hypoglycemic agents.
Several studies have reported that the addition of sulfo-
nylurea or acarbose improved glycemic control in patients
with T2DM unable to achieve or maintain glycemic con-
trol with metformin monotherapy alone [7,27]. It is gener-
ally accepted that sulfonylureas exert their hypoglycemic
effect in part through direct action on pancreatic β-cells,
which augments insulin secretion, although improvements
in insulin sensitivity have also been reported in some, but
not all studies [28-30]. Based on the anti-hyperglycemic
mechanisms of sulfonylurea, it seemed reasonable that
patients with higher baseline DI120 would have a better
treatment response after adding glibencalmide, as seen
in our patients.
Alpha-glucosidase inhibitors, such as acarbose, act via
inhibiting disaccharide hydrolyzing enzymes in the small
intestine, thereby decreasing glucose absorption and im-
proving control over postprandial hyperglycemia. Acarbose
has also been found to improve both insulin resistance and
secretion indirectly in obese patients with T2DM [31,32].
It is postulated that insulin secretion and sensitivity might
have improved at least in part through a decrease in glu-
cose toxicity, because α-glucosidase inhibitors do not have
a direct effect on insulin secretion or sensitivity. It was
speculated that the improvement in HbA1c in the pa-
tients in the acarbose group was a result of cooperative
improvement of insulin sensitivity and secretion after
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function still played a role in the regulation of glycemic re-
sponse after acarbose [33].
The strength of our study is the collection of insulin se-
cretion or insulin sensitivity parameters during LMTT,
which is not easily done in clinical studies. However, this
LMTT was limited by that some subjects still used the in-
vestigational medication (e.g. sulfonylurea) in the evening
before the 2nd LMTT, and thus the DI120 derived from
the 2nd LMTT may reflect drug-stimulated rather than
endogenous residual β-cell function. Second, our study
enrolled small sample size of patients a single ethnic popu-
lation, which might influence statistical power to analyze
whether DI120 was a significant predictor of HbA1c after
combination therapy of metformin with glibenclamide or
acarbose. Third, this study had short washout period, that
might make the baseline HbA1c at inclusion underesti-
mated in patients taking sulfonylurea in comparison to
those selected after metformin monotherapy failure. Fi-
nally, we did not evaluate the other choices of add-on
medication. Further prospective studies with more patients
and longer follow-up are needed to determine the associ-
ation between DI120 and good glycemic control, especially
in connection with different OADs.
Conclusions
Addition of glibenclamide or acarbose resulted in the sig-
nificant HbA1c reduction and improvement of DI120 in pa-
tients poorly controlled with metformin, and post-meal
DI120 predicted the change in HbA1c in each group after
addition of glibenclamide or acarbose. It is suggested that
residual β-cell function reserve may help to predict gly-
cemic control response of combination of these agents.
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